These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26317900)

  • 1. Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
    Venkova L; Aliper A; Suntsova M; Kholodenko R; Shepelin D; Borisov N; Malakhova G; Vasilov R; Roumiantsev S; Zhavoronkov A; Buzdin A
    Oncotarget; 2015 Sep; 6(29):27227-38. PubMed ID: 26317900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics Meets Biomedicine: OncoFinder, a Quantitative Approach for Interrogating Molecular Pathways Using Gene Expression Data.
    Buzdin AA; Prassolov V; Zhavoronkov AA; Borisov NM
    Methods Mol Biol; 2017; 1613():53-83. PubMed ID: 28849558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome profiling in response to adiponectin in human cancer-derived cells.
    Berger E; Rome S; Vega N; Ciancia C; Vidal H
    Physiol Genomics; 2010 Sep; 42A(1):61-70. PubMed ID: 20571111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
    BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of metastatic kidney cancer: the role of new molecular drugs.
    Vitale MG; Cartenì G
    Future Oncol; 2016 Jan; 12(1):83-93. PubMed ID: 26617188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
    Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
    Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on targeted therapy in metastatic renal cell carcinoma.
    Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
    Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse gene expression patterns in response to anticancer drugs between human and mouse cell lines revealed by a comparative transcriptomic analysis.
    Guo Y; Liang Z; Hou X; Zhang Z
    Mol Med Rep; 2017 Oct; 16(4):4469-4474. PubMed ID: 28791417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
    Hess G; Borker R; Fonseca E
    Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
    Liu Y; Wang P; Li S; Yin L; Shen H; Liu R
    Int J Clin Exp Pathol; 2015; 8(3):3027-35. PubMed ID: 26045814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways.
    Lezhnina K; Kovalchuk O; Zhavoronkov AA; Korzinkin MB; Zabolotneva AA; Shegay PV; Sokov DG; Gaifullin NM; Rusakov IG; Aliper AM; Roumiantsev SA; Alekseev BY; Borisov NM; Buzdin AA
    Oncotarget; 2014 Oct; 5(19):9022-32. PubMed ID: 25296972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
    Covell DG
    PLoS One; 2012; 7(10):e44631. PubMed ID: 23056181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
    Artemov A; Aliper A; Korzinkin M; Lezhnina K; Jellen L; Zhukov N; Roumiantsev S; Gaifullin N; Zhavoronkov A; Borisov N; Buzdin A
    Oncotarget; 2015 Oct; 6(30):29347-56. PubMed ID: 26320181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.
    Mashima T; Ushijima M; Matsuura M; Tsukahara S; Kunimasa K; Furuno A; Saito S; Kitamura M; Soma-Nagae T; Seimiya H; Dan S; Yamori T; Tomida A
    Cancer Sci; 2015 Jul; 106(7):909-20. PubMed ID: 25911996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.